Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions

被引:20
作者
Graziani, Gina M. [1 ]
Angel, Jonathan B. [1 ,2 ]
机构
[1] Ottawa Gen Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada
[2] Ottawa Gen Hosp, Div Infect Dis, Ottawa, ON K1H 8L6, Canada
关键词
HIV; AIDS; analytical treatment interruption(s); clinical trials; outcome measure; therapeutic vaccine; vaccine efficacy; viral reservoir; T-CELL RESPONSES; STRUCTURED TREATMENT INTERRUPTION; ACTIVE ANTIRETROVIRAL THERAPY; HEPATITIS-B PATIENTS; PHASE-II TRIAL; CLINICAL-TRIALS; HIV-1-INFECTED PATIENTS; DOUBLE-BLIND; ALVAC-HIV; IMMUNOLOGICAL RESPONSE;
D O I
10.7448/IAS.18.1.20497
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: The development of an effective therapeutic HIV vaccine that induces immunologic control of viral replication, thereby eliminating or reducing the need for antiretroviral therapy (ART), would be of great value. Besides the obvious challenges of developing a therapeutic vaccine that would generate effective, sustained anti-HIV immunity in infected individuals is the issue of how to best assess the efficacy of vaccine candidates. Discussion: This review discusses the various outcome measures assessed in therapeutic HIV vaccine clinical trials involving individuals receiving suppressive ART, with a particular focus on the role of analytical treatment interruption (ATI) as a way to assess the virologic control induced by an immunotherapy. This strategy is critical given that there are otherwise no readily available measures to determine the ability of a vaccine-induced immune response to effectively control HIV replication. The various outcome measures that have been used to assess vaccine efficacy in published therapeutic HIV vaccine clinical trials will also be discussed. Outcome measures have included the kinetics of viral rebound, the new viral set point and changes in the size of the viral reservoir. Clinically relevant outcomes such as the CD4 decline, the time to resume therapy or the time to meet the criterion to resume therapy, the proportion of participants who resume therapy and/or the development of clinical symptoms such as acute retroviral syndrome are also measures of vaccine efficacy. Conclusions: Given the lack of consistency between therapeutic HIV vaccine trials in how efficacy is assessed, comparing vaccines has been difficult. It would, therefore, be beneficial to determine the most clinically relevant measure for use in future studies. Other recommendations for future clinical trials also include studying compartments in addition to blood and replacing ATIs with single-copy assays in situations in which the use of an ATI is not ideal.
引用
收藏
页数:16
相关论文
共 131 条
[1]   Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial [J].
Achenbach, Chad J. ;
Assoumou, Lambert ;
Deeks, Steven G. ;
Wilkin, Timothy J. ;
Berzins, Baiba ;
Casazza, Joseph P. ;
Lambert-Niclot, Sidonie ;
Koup, Richard A. ;
Costagliola, Dominique ;
Calvez, Vincent ;
Katlama, Christine ;
Autran, Brigitte ;
Murphy, Robert L. .
LANCET HIV, 2015, 2 (03) :E82-E91
[2]   MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma - A phase I/II study [J].
Albarran y Carvajal, Antonio ;
de la Garza, Alfonso ;
Cecilio Cruz Quiroz, Benitez Jose ;
Zea, Eduardo Vazquez ;
Estrada, Ismael Diaz ;
Fuentez, Ernesto Mendez ;
Contreras, Mario Lopez ;
Andrade-Manzano, Alejandro ;
Padilla, Santiago ;
Varela, Axel Ramirez ;
Rosales, Ricardo .
BIODRUGS, 2007, 21 (01) :47-59
[3]   A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption [J].
Allard, Sabine D. ;
De Keersmaecker, Brenda ;
de Goede, Anna L. ;
Verschuren, Esther J. ;
Koetsveld, Jeanette ;
Reedijk, Mariska L. ;
Wylock, Carolien ;
De Bel, Annelies V. ;
Vandeloo, Judith ;
Pistoor, Frank ;
Heirman, Carlo ;
Beyer, Walter E. P. ;
Eilers, Paul H. C. ;
Corthals, Jurgen ;
Padmos, Iman ;
Thielemans, Kris ;
Osterhaus, Albert D. M. E. ;
Lacor, Patrick ;
van der Ende, Marchina E. ;
Aerts, Joeri L. ;
van Baalen, Carel A. ;
Gruters, Rob A. .
CLINICAL IMMUNOLOGY, 2012, 142 (03) :252-268
[4]   HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin [J].
Amador-Canizares, Yalena ;
Martinez-Donato, Gillian ;
Alvarez-Lajonchere, Liz ;
Vasallo, Claudia ;
Dausa, Mariacarla ;
Aguilar-Noriega, Daylen ;
Valenzuela, Carmen ;
Raices, Ivette ;
Dubuisson, Jean ;
Wychowski, Czeslaw ;
Cinza-Estevez, Zurina ;
Castellanos, Marlen ;
Nunez, Magdalys ;
Armas, Anny ;
Gonzalez, Yaime ;
Reve, Ismariley ;
Guerra, Ivis ;
Perez Aguiar, Angel ;
Duenas-Carrera, Santiago .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (01) :148-162
[5]   Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection [J].
Ananworanich, J ;
Phanuphak, N ;
Nuesch, R ;
Apateerapong, W ;
Rojnuckarin, P ;
Ubolyam, S ;
Phanuphak, P ;
Ruxrungtham, K .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (05) :723-725
[6]   CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1:: results of the Staccato randomised trial [J].
Ananworanich, Jintanat ;
Gayet-Ageron, Angele ;
Le Braz, Michelle ;
Prasithsirikul, Wisit ;
Chetchotisakd, Ploenchan ;
Kiertiburanakul, Sasisopin ;
Munsakul, Warangkana ;
Raksakulkarn, Phitsanu ;
Tansuphasawasdikul, Somboon ;
Sirivichayakul, Sunee ;
Cavassini, Matthias ;
Karrer, Urs ;
Genne, Daniel ;
Nueesch, Reto ;
Vernazza, Pietro ;
Bernasconi, Enos ;
Leduc, Dominic ;
Satchell, Claudette ;
Yerly, Sabine ;
Perrin, Luc ;
Hill, Andrew ;
Perneger, Thomas ;
Phanuphak, Praphan ;
Furrer, Hansjakob ;
Cooper, David ;
Ruxrungtham, Kiat ;
Hirschel, Bernard .
LANCET, 2006, 368 (9534) :459-465
[7]  
Anderson JL, 2015, AIDS RES HUM RETROV, V31, P36, DOI [10.1089/aid.2014.0236, 10.1089/AID.2014.0236]
[8]   HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses [J].
Andres, Cristina ;
Plana, Montserrat ;
Guardo, Alberto C. ;
Alvarez-Fernandez, Carmen ;
Climent, Nuria ;
Gallart, Teresa ;
Leon, Agathe ;
Clotet, Bonaventura ;
Autran, Brigitte ;
Chomont, Nicolas ;
Gatell, Josep M. ;
Sanchez-Palomino, Sonsoles ;
Garcia, Felipe .
JOURNAL OF VIROLOGY, 2015, 89 (18) :9189-9199
[9]   The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy) [J].
Angel, Jonathan B. ;
Routy, Jean-Pierre ;
Graziani, Gina M. ;
Tremblay, Cecile L. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 70 (02) :122-128
[10]   A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune [J].
Angel, Jonathan B. ;
Routy, Jean-Pierre ;
Tremblay, Cecile ;
Ayers, Dieter ;
Woods, Ryan ;
Singer, Joel ;
Bernard, Nicole ;
Kovacs, Colin ;
Smaill, Fiona ;
Gurunathan, Sanjay ;
Sekaly, Rafick-Pierre .
AIDS, 2011, 25 (06) :731-739